Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy
Corresponding Author
Daniel J. Landsburg
University of Pennsylvania, Philadelphia, PA, USA
Correspondence: Daniel J. Landsburg, University of Pennsylvania, 3400 Civic Center Boulevard, #12-182, Philadelphia, PA 19104, USA.
E-mail: [email protected]
Search for more papers by this authorEmily C. Ayers
University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorNina D. Wagner-Johnston
Johns Hopkins University, Baltimore, MD, USA
Search for more papers by this authorRadhakrishnan Ramchandren
Wayne State University, Detroit, MI, USA
University of Tennessee, Knoxville, TN, USA
Search for more papers by this authorSarit E. Assouline
McGill University Jewish General Hospital, Montreal, QC, Canada
Search for more papers by this authorPallawi Torka
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Search for more papers by this authorAngel Mier Hicks
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Search for more papers by this authorL. Jeffrey Medeiros
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorShaoying Li
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Daniel J. Landsburg
University of Pennsylvania, Philadelphia, PA, USA
Correspondence: Daniel J. Landsburg, University of Pennsylvania, 3400 Civic Center Boulevard, #12-182, Philadelphia, PA 19104, USA.
E-mail: [email protected]
Search for more papers by this authorEmily C. Ayers
University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorNina D. Wagner-Johnston
Johns Hopkins University, Baltimore, MD, USA
Search for more papers by this authorRadhakrishnan Ramchandren
Wayne State University, Detroit, MI, USA
University of Tennessee, Knoxville, TN, USA
Search for more papers by this authorSarit E. Assouline
McGill University Jewish General Hospital, Montreal, QC, Canada
Search for more papers by this authorPallawi Torka
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Search for more papers by this authorAngel Mier Hicks
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Search for more papers by this authorL. Jeffrey Medeiros
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorShaoying Li
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSummary
While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.
Supporting Information
| Filename | Description |
|---|---|
| bjh16319-sup-0001-FigS1.docxWord document, 91.4 KB | Figure S1. Patient selection. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Ayers, E.C., Li, S., Medeiros, J., Bond, D.A., Maddocks, K.J., Torka, P., Mier Hicks, A., Curry, M., Wagner-Johnston, N.D., Karmali, R., Behdad, A., Fakhri, B., Kahl, B.S., Churnetski, M.C., Cohen, J.B., Reddy, N., Modi, D., Ramchandren, R., Howlett, C., Leslie, L.A., Cytryn, S., Diefenbach, C., Faramand, R., Chavez, J.C., Olszewski, A.J., Liu, Y., Barta, S.K., Mukhija, D., Hill, B.T., Ma, H., Amengual, J.E., Nathan, S., Assouline, S., Orellana-Noia, V.M., Portell, C.A., Chandar, A., David, K.A., Giri, A., Hess, B.T. & Landsburg, D.J. (2018) Outcome of patients with aggressive B cell lymphomas who receive second-line salvage immunochemotherapy following treatment failure of intensive first-line immunochemotherapy. Blood, 132, 453–453.
- Brankley, S.M., Adams, E.J., Christensen, M.R., Everts, C.R., Lund, J.D., Oberg, T.N., Plagge, A.M., Zieman, A.H., Kipp, B.R. & Halling, K.C. (2008) A study of the reproducibility of a fluorescence in situ hybridization bladder cancer detection assay. Analytical and Quantitative Cytology and Histology, 30, 145–151.
- Cuccuini, W., Briere, J., Mounier, N., Voelker, H.U., Rosenwald, A., Sundstrom, C., Cogliatti, S., Hirchaud, E., Ysebaert, L., Bron, D., Soulier, J., Gaulard, P., Houlgatte, R., Gisselbrecht, C. & Thieblemont, C. (2012) MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood, 119, 4619–4624.
- Dunleavy, K., Fanale, M.A., Abramson, J.S., Noy, A., Caimi, P.F., Pittaluga, S., Parekh, S., Lacasce, A., Hayslip, J.W., Jagadeesh, D., Nagpal, S., Lechowicz, M.J., Gaur, R., Lucas, A., Melani, C., Roschewski, M., Steinberg, S.M., Jaffe, E.S., Kahl, B., Friedberg, J.W., Little, R.F., Bartlett, N.L. & Wilson, W.H. (2018) Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. The Lancet Haematology, 5, e609–e617.
- Howlett, C., Snedecor, S.J., Landsburg, D.J., Svoboda, J., Chong, E.A., Schuster, S.J., Nasta, S.D., Feldman, T., Rago, A., Walsh, K.M., Weber, S., Goy, A. & Mato, A. (2015) Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. British Journal of Haematology, 170, 504–514.
- Hu, S., Xu-Monette, Z.Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.M., Visco, C., Li, Y., Miranda, R.N., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W., Zhao, X., van Krieken, J.H., Huang, Q., Huh, J., Ai, W., Ponzoni, M., Ferreri, A.J., Zhou, F., Slack, G.W., Gascoyne, R.D., Tu, M., Variakojis, D., Chen, W., Go, R.S., Piris, M.A., Moller, M.B., Medeiros, L.J. & Young, K.H. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 121, 4021–4031; quiz 4250.
- Petrich, A.M., Gandhi, M., Jovanovic, B., Castillo, J.J., Rajguru, S., Yang, D.T., Shah, K.A., Whyman, J.D., Lansigan, F., Hernandez-Ilizaliturri, F.J., Lee, L.X., Barta, S.K., Melinamani, S., Karmali, R., Adeimy, C., Smith, S., Dalal, N., Nabhan, C., Peace, D., Vose, J., Evens, A.M., Shah, N., Fenske, T.S., Zelenetz, A.D., Landsburg, D.J., Howlett, C., Mato, A., Jaglal, M., Chavez, J.C., Tsai, J.P., Reddy, N., Li, S., Handler, C., Flowers, C.R., Cohen, J.B., Blum, K.A., Song, K., Sun, H.L., Press, O., Cassaday, R., Jaso, J., Medeiros, L.J., Sohani, A.R. & Abramson, J.S. (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood, 124, 2354–2361.
- Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L. & Coiffier, B. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540–1545.
- Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D. & Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127, 2375–2390.
- Van Den Neste, E., Schmitz, N., Mounier, N., Gill, D., Linch, D., Trneny, M., Milpied, N., Radford, J., Ketterer, N., Shpilberg, O., Duhrsen, U., Ma, D., Briere, J., Thieblemont, C., Salles, G., Moskowitz, C.H., Glass, B. & Gisselbrecht, C. (2016) Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplantation, 51, 51–57.
- Zhang, G., Lanigan, C.P., Goldblum, J.R., Tubbs, R.R. & Downs-Kelly, E. (2016) automated bright-field dual-color in situ hybridization for MDM2: interobserver reproducibility and correlation with fluorescence in situ hybridization in a series of soft tissue consults. Archives of Pathology and Laboratory Medicine, 140, 1111–1115.
Citing Literature
